Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics.
暂无分享,去创建一个
L. Luttrell | Stuart Maudsley | L M Luttrell | S Maudsley | S A Patel | S-S Park | B Martin | S. A. Patel | S-S Park | B. Martin
[1] R. Lefkowitz,et al. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.
[2] Jiaquan Xu,et al. Death in the United States, 2007. , 2009, NCHS data brief.
[3] L. Luttrell,et al. Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling , 2010, Pharmacological Reviews.
[4] M. Böhm,et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.
[5] Stuart Maudsley,et al. Minimal Peroxide Exposure of Neuronal Cells Induces Multifaceted Adaptive Responses , 2010, PloS one.
[6] Stuart Maudsley,et al. The Origins of Diversity and Specificity in G Protein-Coupled Receptor Signaling , 2005, Journal of Pharmacology and Experimental Therapeutics.
[7] Bruce S. McEwen,et al. Allostasis and Allostatic Load , 2007 .
[8] Adam J Pawson,et al. Gonadotropin-Releasing Hormone Functionally Antagonizes Testosterone Activation of the Human Androgen Receptor in Prostate Cells through Focal Adhesion Complexes Involving Hic-5 , 2007, Neuroendocrinology.
[9] J. Violin,et al. β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection , 2007 .
[10] S. W. Jones,et al. Commentary: a plausible model. , 1999, The Journal of general physiology.
[11] L. Kunkel,et al. Syntrophin binds to an alternatively spliced exon of dystrophin , 1995, The Journal of cell biology.
[12] Adam J Pawson,et al. Proline-rich tyrosine kinase 2 mediates gonadotropin-releasing hormone signaling to a specific extracellularly regulated kinase-sensitive transcriptional locus in the luteinizing hormone beta-subunit gene. , 2007, Molecular endocrinology.
[13] R. Mullins,et al. β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.
[14] K. Becker,et al. Growth Factor Signals in Neural Cells , 2009, Journal of Biological Chemistry.
[15] W. Koch,et al. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. , 2007, Trends in molecular medicine.
[16] M. Mattson,et al. Hormesis : a revolution in biology, toxicology and medicine , 2010 .
[17] P. Leff,et al. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.
[18] R. Lefkowitz,et al. Platelet-Derived Growth Factor Receptor Association with Na+/H+ Exchanger Regulatory Factor Potentiates Receptor Activity , 2000, Molecular and Cellular Biology.
[19] C. Hague,et al. Blood Pressure Is Regulated by an α1D-Adrenergic Receptor/Dystrophin Signalosome* , 2008, Journal of Biological Chemistry.
[20] R. Lefkowitz,et al. β-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor Stimulation* , 2002, The Journal of Biological Chemistry.
[21] B. Kobilka,et al. Myocyte Adrenoceptor Signaling Pathways , 2003, Science.
[22] S. Shenolikar,et al. The β2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange , 1998, Nature.
[23] G. Grassi,et al. Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. , 2009, Current vascular pharmacology.
[24] L. Luttrell. Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity , 2007, Journal of Molecular Neuroscience.
[25] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.
[26] L. Kunkel,et al. Cloning of human basic A1, a distinct 59-kDa dystrophin-associated protein encoded on chromosome 8q23-24. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] R. Lefkowitz,et al. A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.
[28] A. IJzerman,et al. Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist‐specific G protein activation , 2004, British journal of pharmacology.
[29] T. Kenakin. Functional Selectivity and Biased Receptor Signaling , 2011, Journal of Pharmacology and Experimental Therapeutics.
[30] T. Kohout,et al. Targeting of Cyclic AMP Degradation to β2-Adrenergic Receptors by β-Arrestins , 2002, Science.
[31] J. Cartaud,et al. Identification of dystrophin-binding protein(s) in membranes from Torpedo electrocyte and rat muscle. , 1993, The Journal of biological chemistry.
[32] T. Kenakin,et al. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.
[33] A Karlin,et al. On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. , 1967, Journal of theoretical biology.
[34] L. Luttrell,et al. Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2 alpha-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. , 2003, Molecular endocrinology.
[35] T. Kohout,et al. Regulation of Receptor Fate by Ubiquitination of Activated β2-Adrenergic Receptor and β-Arrestin , 2001, Science.
[36] R. Seifert,et al. Differential coupling of the human cannabinoid receptors hCB1R and hCB2R to the G-protein Gαi2β1γ2 , 2008, Neuroscience Letters.
[37] C. Christodoulou,et al. Self-control with spiking and non-spiking neural networks playing games , 2010, Journal of Physiology-Paris.
[38] Adam J Pawson,et al. Gonadotropin-releasing Hormone-induced Activation of Diacylglycerol Kinase-ζ and Its Association with Active c-Src* , 2004, Journal of Biological Chemistry.
[39] J. Wingfield,et al. The concept of allostasis in biology and biomedicine , 2003, Hormones and Behavior.
[40] T. Ebisawa,et al. A novel scheme of dystrophin disruption for the progression of advanced heart failure. , 2005, Biochimica et biophysica acta.
[41] J. Schaper,et al. The Cytoskeleton and Related Proteins in the Human Failing Heart , 2000, Heart Failure Reviews.
[42] R Seifert,et al. Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. , 1999, Molecular pharmacology.
[43] Adam J Pawson,et al. Gonadotropin-Releasing Hormone (GnRH) Antagonists Promote Proapoptotic Signaling in Peripheral Reproductive Tumor Cells by Activating a Gαi-Coupling State of the Type I GnRH Receptor , 2004, Cancer Research.
[44] Xin Lin,et al. β-Arrestin 2 is required for lysophosphatidic acid-induced NF-κB activation , 2008, Proceedings of the National Academy of Sciences.
[45] C. Hague,et al. Syntrophin isoforms play specific functional roles in the α1D-adrenergic receptor/DAPC signalosome. , 2011, Biochemical and biophysical research communications.
[46] T. Sotnikova,et al. An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.
[47] S. Liggett,et al. Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. , 1994, Molecular pharmacology.
[48] L. Luttrell. Reviews in Molecular Biology and Biotechnology: Transmembrane Signaling by G Protein-Coupled Receptors , 2008, Molecular biotechnology.
[49] B. Kobilka,et al. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. , 2001, The Journal of pharmacology and experimental therapeutics.
[50] G. Martin,et al. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. , 1998, The Journal of pharmacology and experimental therapeutics.
[51] S. Maayani,et al. Pleiotropic Behavior of 5‐HT2A and 5‐HT2C Receptor Agonists , 1998, Annals of the New York Academy of Sciences.
[52] J. Finsterer,et al. The Heart in Human Dystrophinopathies , 2003, Cardiology.
[53] P. Tonali,et al. γ1- and γ2-Syntrophins, Two Novel Dystrophin-binding Proteins Localized in Neuronal Cells* , 2000, The Journal of Biological Chemistry.
[54] R. Lefkowitz,et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.
[55] W. Paulus,et al. Myofilament dysfunction in cardiac disease from mice to men , 2008, Journal of Muscle Research and Cell Motility.
[56] J. M. Smith,et al. The Logic of Animal Conflict , 1973, Nature.
[57] R. A. Hall,et al. Fine-tuning of GPCR activity by receptor-interacting proteins , 2009, Nature Reviews Molecular Cell Biology.
[58] Jyrki P. Kukkonen,et al. Agonist trafficking of Gi/o‐mediated α2A‐adrenoceptor responses in HEL 92.1.7 cells , 2001 .
[59] K. Flegal,et al. Prevalence and trends in obesity among US adults, 1999-2008. , 2010, JAMA.
[60] T. Kenakin. Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? , 2007, Molecular Pharmacology.
[61] L. Luttrell,et al. G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. , 2007, Current Alzheimer research.
[62] Graeme Milligan,et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.
[63] Melanie G. Lee,et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.
[64] R. Lefkowitz,et al. Targeting of Diacylglycerol Degradation to M1 Muscarinic Receptors by ß-Arrestins , 2007, Science.
[65] R. Lefkowitz,et al. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.
[66] S. Ferguson,et al. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.
[67] M. Caron,et al. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. , 1992, The Journal of biological chemistry.
[68] Ted L. Anderson,et al. On the Application of R -Curves and Maximum Load Toughness to Structures , 1988 .
[69] M. Caron,et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.
[70] L. Luttrell,et al. ‘Biasing’ the parathyroid hormone receptor: A novel anabolic approach to increasing bone mass? , 2011, British journal of pharmacology.
[71] M. F. Peters,et al. Two forms of mouse syntrophin, a 58 kd dystrophin-associated protein, differ in primary structure and tissue distribution , 1993, Neuron.